ImageneBio, Inc.
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at ImageneBio, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 4.60 $ to 8.80 $ · Last price: 5.00 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| ImageneBio, Inc. IMA | 0.1 | – | 0.0 | – | – | -77.1 | -39.9 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 57.0 | 21.8 | 5.1 | 33.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 1 | -41 | -41 | -13.68 | -12 | -46 | 21 |
| 2019 | 14 | -18 | -17 | -5.63 | 48 | -61 | 86 |
| 2020 | 9 | -45 | -44 | -14.81 | -38 | -101 | 168 |
| 2021 | 31 | -34 | -34 | -11.38 | -60 | 208 | 248 |
| 2022 | 16 | -71 | -69 | -22.80 | -74 | 147 | 172 |
| 2023 | 9 | -75 | -68 | -19.60 | -80 | 170 | 192 |
| 2024 | 4 | -37 | -37 | -30.62 | -46 | 126 | 142 |
| 2025 | 1 | -48 | -45 | -8.35 | -48 | 133 | 153 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.81 | – | 0 | -100.00 | – | -6 | -6 |
| 2025: Q1 | -0.76 | – | 1 | – | -1,077.40 | -11 | -11 |
| 2025: Q2 | -0.25 | – | – | – | – | -3 | -3 |
| 2025: Q3 | -2.20 | – | 0 | -100.00 | – | -27 | -27 |
| 2025: Q4 | -0.61 | – | 0 | – | – | -7 | -7 |
| 2026: Q1 | -0.94 | – | 0 | -100.00 | – | -15 | -15 |
| 2026: Q2 | -0.63 | -152.00 | – | – | – | -9 | -9 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
Risk & Weakness
Value & GARP
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.31 | -3.57 – -3.18 | 0 | 65.7% | 3 |
| 12/31/2027 | -4.31 | -5.48 – -2.99 | 0 | -30.2% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
ImageneBio ist trotz des KI-anmutenden Namens (eine Eindeutschung von »Inmagene«, dem fusionierten Biopharma-Unternehmen) eine klinische Ein-Produkt-Biotech: Leit- und einziger Wirkstoff ist der nicht-depletierende Anti-OX40-Antikörper IMG-007 gegen Neurodermitis. Kein KI-Produkt, kein KI-Umsatz (die Firma erzielt überhaupt keinen Produktumsatz), also kein »verkauft«. Kein »bedroht«: In den Risk Factors taucht »artificial intelligence« nur als generische Bedrohungs-/Regulierungs-Floskel auf (KI-gestützte Cyberangriffe, Deep Fakes, KI-Sektor-Regulierung nach OISP) ohne konkreten Bezug zum eigenen Geschäftsmodell. Auch kein »nutzt«: Der einzige Hinweis auf tatsächlichen KI-Einsatz ist ein beiläufiger Satz innerhalb eines Datenschutz-Risikofaktors, wonach Mitarbeiter generative KI-Werkzeuge bei ihrer Arbeit nutzen — kein dokumentiertes, wertschöpfendes KI-Programm (Effizienz/interne Produkte). Nach dem Kriterienkatalog verbleibt damit »Neutral« mit dokumentiertem Negativ-Befund; alle sechs ausgewerteten Filings sind gelistet.
View the full file — quotes, sources, reviewed filings
„As a result of the Non-OX40 Divestiture, IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of AD and other potential indications, became the only product candidate we have in clinical development."
Infolge der Non-OX40-Abspaltung wurde IMG-007, ein nicht-depletierender monoklonaler Anti-OX40-Antikörper zur Behandlung von Neurodermitis und weiteren möglichen Indikationen, zum einzigen Produktkandidaten, den wir in klinischer Entwicklung haben.
10-K · 2026-03-10 · View SEC filing
„Our personnel use generative artificial intelligence (“AI”) technologies to perform their work, and the disclosure and use of personal data in AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiter nutzen generative Technologien der Künstlichen Intelligenz („KI“) bei ihrer Arbeit, und die Offenlegung und Nutzung personenbezogener Daten in KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und weiteren Datenschutzpflichten.
10-K · 2026-03-10 · View SEC filing
Filings Reviewed: 10-Q 2026-05-07 · 10-Q 2025-11-12 · 10-Q 2025-07-24 · 10-Q 2025-05-08 · 10-K 2026-03-10 · 10-K 2025-03-06
Rated on July 10, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -62.9%
- More than 10% revenue growth is expected for the coming year 0.0%
- Share count grows by less than 3% a year 21.7%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -6,057.6%
- Gross margin at 40% or higher and without meaningful erosion -29.1%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 66 m net cash
- Operating cash flow covers the profits of the last three years -24 m
- Return on capital at 15% or higher, or up versus two years ago -34.2%
- Insiders hold at least 10% or are net buyers 15.0%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -3.0%
- Exp. sales growth 3Y > 5% -100.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -100.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -34.1%
- ROCE > 15% -34.2%
- Expected return > 10% -100.0%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Grant-Huerta Yanina | Chief Financial Officer | Other | 39,000 | 0.00 | – |
| Aug 14, 2026 | Grant-Huerta Yanina | Chief Financial Officer | Other | 65,000 | 0.00 | – |
| Aug 14, 2026 | Yarema Kristin | Chief Executive Officer | Other | 254,800 | 0.00 | – |
| Jul 25, 2026 | Yarema Kristin | Chief Executive Officer | Other | 115,129 | 0.00 | – |
| Jul 25, 2026 | Yarema Kristin | Chief Executive Officer | Other | 38,376 | 0.00 | – |
| Jul 17, 2026 | Lally Robert B | Principal Accounting Officer | Sell | 1,525 | 5.34 | 8,144 |
| Jul 16, 2026 | Lally Robert B | Principal Accounting Officer | Sell | 1,671 | 5.50 | 9,191 |
The company
About the Company
ImageneBio, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt Therapeutika für Patienten mit immunologischen, autoimmunen und entzündlichen Erkrankungen.
- Employees
- 18
- Headquarters
- San Diego, CA
- Address
- 12526 High Bluff Drive, 92130 San Diego, United States
- Phone
- 858 345 6265
- Website
- inmagenebio.com
- IPO Date
- 03/26/2021
- ISIN
- US45175G2075
- Stock Split
- 1:12 on 07/28/2025
Management
| Name | Title | Birth Year |
|---|---|---|
| Kristin Yarema Ph.D. | CEO & Director | 1971 |
| Yanina Grant-Huerta | CFO, Principal Financial Officer & Principal Accounting Officer | 1977 |
| Kurinji Pandiyan Ph.D. | Chief Strategy & Operations Officer | – |
| Renuka Sivendran Ph.D. | Chief Technical Officer | – |
| Matt Robbins J.D. | General Counsel | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/05/2026 ImageneBio, Inc. (IMA): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/23/2026 ImageneBio, Inc. (IMA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.